Membrane transporters in drug development
Open accessThe DOI matches its Crossref record; 225 of the 225 references it cites were found in a registry or an index.
Abstract
Membrane transporters can be major determinants of the pharmacokinetic, safety and efficacy profiles of drugs. This presents several key questions for drug development, including which transporters are clinically important in drug absorption and disposition, and which in vitro methods are suitable for studying drug interactions with these transporters. In addition, what criteria should trigger follow-up clinical studies, and which clinical studies should be conducted if needed. In this article, we provide the recommendations of the International Transporter Consortium on these issues, and present decision trees that are intended to help guide clinical studies on the currently recognized most important drug transporter interactions. The recommendations are generally intended to support clinical development and filing of a new drug application. Overall, it is advised that the timing of transporter investigations should be driven by efficacy, safety and clinical trial enrolment questions (for example, exclusion and inclusion criteria), as well as a need for further understanding of the absorption, distribution, metabolism and excretion properties of the drug molecule, and information required for drug labelling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“To date, the human genome has been proven to have more than 400 membrane transporters, which are divided into two families: ATP binding cassette (ABC) and solute carrier (SLC) transporters [114].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [114]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,782
Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R. (1995) · Pharmaceutical Research · doi:10.1023/a:1016212804288 · Cited by 5,430
A multidrug resistance transporter from human MCF-7 breast cancer cells
Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., & Ross, D. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15665 · Cited by 2,322
Schinkel, A. H., Smit, J. J. M., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., van der Valk, M. A., Robanus-Maandag, E. C., te Riele, H. P. J., et al. (1994) · Cell · doi:10.1016/0092-8674(94)90212-7 · Cited by 2,281
SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801936 · Cited by 2,043
Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding
Aller, S. G., Yu, J., Ward, A., Weng, Y., Chittaboina, S., Zhuo, R., Harrell, P. M., Trinh, Y. T., Zhang, Q., Urbatsch, I. L., et al. (2009) · Science · doi:10.1126/science.1168750 · Cited by 1,929
Wu, C.-Y., & Benet, L. Z. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-9004-4 · Cited by 1,401
Self-citationMammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview
Schinkel, A. H., & Jonker, J. W. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00169-2 · Cited by 1,386
Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview
Schinkel, A. H., & Jonker, J. W. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.027 · Cited by 1,231
Koepsell, H., Lips, K., & Volk, C. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9254-z · Cited by 988
Hediger, M. A., Romero, M. F., Peng, J.-B., Rolfs, A., Takanaga, H., & Bruford, E. A. (2004) · Pfl�gers Archiv European Journal of Physiology · doi:10.1007/s00424-003-1192-y · Cited by 985
Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action
Shu, Y., Sheardown, S. A., Brown, C., Owen, R. P., Zhang, S., Castro, R. A., Ianculescu, A. G., Yue, L., Lo, J. C., Burchard, E. G., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30558 · Cited by 967
Self-citationThe superfamily of organic anion transporting polypeptides
Hagenbuch, B., & Meier, P. J. (2003) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(02)00633-8 · Cited by 861
Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance
NEUVONEN, P., NIEMI, M., & BACKMAN, J. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.09.003 · Cited by 859
Self-citationWacher, V. J., Wu, C., & Benet, L. Z. (1995) · Molecular Carcinogenesis · doi:10.1002/mc.2940130302 · Cited by 857
Self-citation(2001) · Drugs and the Pharmaceutical Sciences · doi:10.1201/9780824741969.axh · Cited by 818
Kullak-Ublick, G. A., Ismair, M. G., Stieger, B., Landmann, L., Huber, R., Pizzagalli, F., Fattinger, K., Meier, P. J., & Hagenbuch, B. (2001) · Gastroenterology · doi:10.1053/gast.2001.21176 · Cited by 723
Lown, K. S., Mayo, R. R., Leichtman, A. B., Hsiao, H.-L., Turgeon, D. K., Schmiedlin-Ren, P., Brown, M. B., Guo, W., Rossi, S. J., Benet, L. Z., et al. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90027-8 · Cited by 680
Self-citationA Novel Human Hepatic Organic Anion Transporting Polypeptide (OATP2)
Hsiang, B., Zhu, Y., Wang, Z., Wu, Y., Sasseville, V., Yang, W.-P., & Kirchgessner, T. G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.52.37161 · Cited by 641
Tirona, R. G., Leake, B. F., Merino, G., & Kim, R. B. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103792200 · Cited by 626
Self-citationKönig, J., Cui, Y., Nies, A. T., & Keppler, D. (2000) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.2000.278.1.g156 · Cited by 620
Self-citationStructure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition
Zhou, S.-F. (2008) · Xenobiotica · doi:10.1080/00498250701867889 · Cited by 599
Hilgendorf, C., Ahlin, G., Seithel, A., Artursson, P., Ungell, A.-L., & Karlsson, J. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.014902 · Cited by 583
Drug Interaction Studies: Study Design, Data Analysis, and Implications for Dosing and Labeling
Huang, S.-M., Temple, R., Throckmorton, D. C., & Lesko, L. J. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100054 · Cited by 579
Identification of a Novel Gene Family Encoding Human Liver-specific Organic Anion Transporter LST-1
Abe, T., Kakyo, M., Tokui, T., Nakagomi, R., Nishio, T., Nakai, D., Nomura, H., Unno, M., Suzuki, M., Naitoh, T., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.24.17159 · Cited by 543
The SLC22 drug transporter family
Koepsell, H., & Endou, H. (2004) · Pfl�gers Archiv European Journal of Physiology · doi:10.1007/s00424-003-1089-9 · Cited by 525
The Gut as a Barrier to Drug Absorption: Combined Role of Cytochrome P450 3A and P-Glycoprotein
Zhang, Y., & Benet, L. Z. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140030-00002 · Cited by 518
Self-citationIto, K., Iwatsubo, T., Kanamitsu, S., Ueda, K., Suzuki, H., & Sugiyama, Y. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01372-3 · Cited by 512
Self-citationFunctional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex.
Piwnica-Worms, D. R., Chiu, M. L., Budding, M., Kronauge, J. F., Kramer, R. A., & Croop, J. M. (1993) · PubMed · Cited by 512
Nishizato, Y. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00060-2 · Cited by 511
Transporters as a determinant of drug clearance and tissue distribution
Shitara, Y., Horie, T., & Sugiyama, Y. (2006) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2005.12.003 · Cited by 496
Self-citationLEE, E., RYAN, S., BIRMINGHAM, B., ZALIKOWSKI, J., MARCH, R., AMBROSE, H., MOORE, R., LEE, C., CHEN, Y., & SCHNECK, D. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.013 · Cited by 480
Self-citationEffect of Genetic Variation in the Organic Cation Transporter 1, OCT1, on Metformin Pharmacokinetics
Shu, Y., Brown, C., Castro, R., Shi, R., Lin, E., Owen, R., Sheardown, S., Yue, L., Burchard, E., Brett, C., et al. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100275 · Cited by 477
Self-citationSLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid
Pasanen, M. K., Neuvonen, M., Neuvonen, P. J., & Niemi, M. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000230416.82349.90 · Cited by 470
Self-citationKruijtzer, C. M. F., Beijnen, J. H., Rosing, H., ten Bokkel Huinink, W. W., Schot, M., Jewell, R. C., Paul, E. M., & Schellens, J. H. M. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.12.116 · Cited by 464
Robey, R. W., To, K. K. K., Polgar, O., Dohse, M., Fetsch, P., Dean, M., & Bates, S. E. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.11.003 · Cited by 449
Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the Hepatic Uptake of Pitavastatin in Humans
Hirano, M., Maeda, K., Shitara, Y., & Sugiyama, Y. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.068056 · Cited by 443
Self-citationInvolvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin
Wang, D.-S., Jonker, J. W., Kato, Y., Kusuhara, H., Schinkel, A. H., & Sugiyama, Y. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.034140 · Cited by 441
Self-citationFeng, B., Mills, J. B., Davidson, R. E., Mireles, R. J., Janiszewski, J. S., Troutman, M. D., & de Morais, S. M. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.017434 · Cited by 440
The Role of Transporters in the Pharmacokinetics of Orally Administered Drugs
Shugarts, S., & Benet, L. Z. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-9924-0 · Cited by 438
Self-citationWhite, D. L., Saunders, V. A., Dang, P., Engler, J., Zannettino, A. C. W., Cambareri, A. C., Quinn, S. R., Manley, P. W., & Hughes, T. P. (2006) · Blood · doi:10.1182/blood-2005-11-4687 · Cited by 435
The Utility of in Vitro Cytochrome P450 Inhibition Data in the Prediction of Drug-Drug Interactions
Obach, R. S., Walsky, R. L., Venkatakrishnan, K., Gaman, E. A., Houston, J. B., & Tremaine, L. M. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.093229 · Cited by 433
Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin
Pasanen, M. K., Fredrikson, H., Neuvonen, P. J., & Niemi, M. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100220 · Cited by 432
Self-citationIncreased drug delivery to the brain by P-glycoprotein inhibition
Sadeque, A. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.109156 · Cited by 426
ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin
Keskitalo, J. E., Zolk, O., Fromm, M. F., Kurkinen, K. J., Neuvonen, P. J., & Niemi, M. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.79 · Cited by 416
Self-citationChoudhuri, S., & Klaassen, C. D. (2006) · International Journal of Toxicology · doi:10.1080/10915810600746023 · Cited by 415
Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family
Hagenbuch, B., & Gui, C. (2008) · Xenobiotica · doi:10.1080/00498250801986951 · Cited by 412
SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid
Tornio, A., Vakkilainen, J., Neuvonen, M., Backman, J. T., Neuvonen, P. J., & Niemi, M. (2015) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000148 · Cited by 409
Self-citationHuang, S., Strong, J. M., Zhang, L., Reynolds, K. S., Nallani, S., Temple, R., Abraham, S., Habet, S. A., Baweja, R. K., Burckart, G. J., et al. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007312153 · Cited by 396
Self-citationMiller, D. S., Bauer, B., & Hartz, A. M. S. (2008) · Pharmacological Reviews · doi:10.1124/pr.107.07109 · Cited by 392
Involvement of Multiple Transporters in the Hepatobiliary Transport of Rosuvastatin
Kitamura, S., Maeda, K., Wang, Y., & Sugiyama, Y. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.021410 · Cited by 361
Self-citationNIEMI, M., BACKMAN, J., KAJOSAARI, L., LEATHART, J., NEUVONEN, M., DALY, A., EICHELBAUM, M., KIVISTO, K., & NEUVONEN, P. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.01.018 · Cited by 360
Self-citationRole of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs
Cascorbi, I. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.04.009 · Cited by 355
Watanabe, T., Kusuhara, H., Maeda, K., Shitara, Y., & Sugiyama, Y. (2009) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.146647 · Cited by 351
Self-citationShitara, Y., Itoh, T., Sato, H., Li, A. P., & Sugiyama, Y. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.041921 · Cited by 340
Self-citationEVALUATION OF DRUG-DRUG INTERACTION IN THE HEPATOBILIARY AND RENAL TRANSPORT OF DRUGS
Shitara, Y., Sato, H., & Sugiyama, Y. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.44.101802.121444 · Cited by 336 · cited 1×
“laevis oocytes, recombinant virus, or stable cell lines expressing an individual or multiple transporter”
BackgroundSelf-citationWhite, D. L., Saunders, V. A., Dang, P., Engler, J., Venables, A., Zrim, S., Zannettino, A., Lynch, K., Manley, P. W., & Hughes, T. (2007) · Blood · doi:10.1182/blood-2007-06-093617 · Cited by 331
SIMONSON, S. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.03.010 · Cited by 330
Active secretion and enterocytic drug metabolism barriers to drug absorption
Wacher, V. J., Salphati, L., & Benet, L. Z. (1996) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(95)00127-s · Cited by 308
Self-citationClinical Pharmacokinetics of the Antiviral Nucleotide Analogues Cidofovir and Adefovir
Cundy, K. C. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199936020-00004 · Cited by 303
DRUG-DRUG INTERACTION BETWEEN PITAVASTATIN AND VARIOUS DRUGS VIA OATP1B1
Hirano, M., Maeda, K., Shitara, Y., & Sugiyama, Y. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.009290 · Cited by 302
Self-citationTreiber, A., Schneiter, R., Häusler, S., & Stieger, B. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.013615 · Cited by 299
Evidence for inverse effects of OATP-C (SLC21A6) *5 and *1b haplotypes on pravastatin kinetics
Mwinyi, J. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.12.016 · Cited by 293
Noé, J., Portmann, R., Brun, M.-E., & Funk, C. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.012930 · Cited by 291
Digoxin-Quinidine Interaction: Pharmacokinetic Evaluation
Hager, W. D., Fenster, P., Mayersohn, M., Perrier, D., Graves, P., Marcus, F. I., & Goldman, S. (1979) · New England Journal of Medicine · doi:10.1056/nejm197905313002202 · Cited by 291
Mikkaichi, T., Suzuki, T., Onogawa, T., Tanemoto, M., Mizutamari, H., Okada, M., Chaki, T., Masuda, S., Tokui, T., Eto, N., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0304987101 · Cited by 289
Tucker, G. T., Houston, J. B., & Huang, S. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.temp.1441.x · Cited by 284
Self-citationThe effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine*
Gomez, D. Y., Wacher, V. J., Tomlanovich, S. J., Hebert, M. F., & Benet, L. Z. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90067-5 · Cited by 282
Self-citationReduction of metformin renal tubular secretion by cimetidine in man.
Somogyi, A., Stockley, C., Keal, J., Rolan, P., & Bochner, F. (1987) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1987.tb03090.x · Cited by 282
OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine
Wang, Z.-J., Yin, O. Q. P., Tomlinson, B., & Chow, M. S. S. (2008) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328302cd41 · Cited by 281
Rizwan, A. N., & Burckhardt, G. (2007) · Pharmaceutical Research · doi:10.1007/s11095-006-9181-4 · Cited by 275
Fenner, K., Troutman, M., Kempshall, S., Cook, J., Ware, J., Smith, D., & Lee, C. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.195 · Cited by 272
Self-citationSASONGKO, L., LINK, J., MUZI, M., MANKOFF, D., YANG, X., COLLIER, A., SHONER, S., & UNADKAT, J. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.01.022 · Cited by 271
de Vries, N. A., Zhao, J., Kroon, E., Buckle, T., Beijnen, J. H., & van Tellingen, O. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1335 · Cited by 270
Genetic Variants of the Organic Cation Transporter 2 Influence the Disposition of Metformin
Song, I., Shin, H., Shim, E., Jung, I., Kim, W., Shon, J., & Shin, J. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.61 · Cited by 268
LeCluyse, E. L., Audus, K. L., & Hochman, J. H. (1994) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1994.266.6.c1764 · Cited by 266
Jonker, J. W., Wagenaar, E., van Eijl, S., & Schinkel, A. H. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.21.7902-7908.2003 · Cited by 265
Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males
Zhang, W., Yu, B.-N., He, Y.-J., Fan, L., Li, Q., Liu, Z.-Q., Wang, A., Liu, Y.-L., Tan, Z.-R., Fen-Jiang, et al. (2006) · Clinica Chimica Acta · doi:10.1016/j.cca.2006.05.010 · Cited by 263
Drug specificity and intestinal membrane localization of human organic cation transporters (OCT)
Müller, J., Lips, K. S., Metzner, L., Neubert, R. H. H., Koepsell, H., & Brandsch, M. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.09.011 · Cited by 262
Polli, J. W., Olson, K. L., Chism, J. P., John-Williams, L. S., Yeager, R. L., Woodard, S. M., Otto, V., Castellino, S., & Demby, V. E. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.024646 · Cited by 256
Self-citationInvolvement of BCRP (ABCG2) in the Biliary Excretion of Pitavastatin
Hirano, M., Maeda, K., Matsushima, S., Nozaki, Y., Kusuhara, H., & Sugiyama, Y. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.014019 · Cited by 256
Self-citationChen, Y., Li, S., Brown, C., Cheatham, S., Castro, R. A., Leabman, M. K., Urban, T. J., Chen, L., Yee, S. W., Choi, J. H., et al. (2009) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32832cc7e9 · Cited by 248
Self-citationWacher, V. J., Salphati, L., & Benet, L. Z. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00126-5 · Cited by 245
Self-citationPhysiological and pharmacological roles of ABCG2 (BCRP): Recent findings in Abcg2 knockout mice
Vlaming, M. L. H., Lagas, J. S., & Schinkel, A. H. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.08.007 · Cited by 243
Pharmacogenetics of ABCG2 and Adverse Reactions to Gefitinib
Cusatis, G., Gregorc, V., Li, J., Spreafico, A., Ingersoll, R. G., Verweij, J., Ludovini, V., Villa, E., Hidalgo, M., Sparreboom, A., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj469 · Cited by 241
Yamazaki, M., Neway, W. E., Ohe, T., Chen, I.-W., Rowe, J. F., Hochman, J. H., Chiba, M., & Lin, J. H. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38809-3 · Cited by 238
Eraly, S. A., Vallon, V., Vaughn, D. A., Gangoiti, J. A., Richter, K., Nagle, M., Monte, J. C., Rieg, T., Truong, D. M., Long, J. M., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m508050200 · Cited by 232
Single nucleotide polymorphisms modify the transporter activity of ABCG2
Morisaki, K., Robey, R. W., Özvegy-Laczka, C., Honjo, Y., Polgar, O., Steadman, K., Sarkadi, B., & Bates, S. E. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0931-x · Cited by 230
Sasaki, M., Suzuki, H., Ito, K., Abe, T., & Sugiyama, Y. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109081200 · Cited by 228
Self-citationMerino, G., Jonker, J. W., Wagenaar, E., van Herwaarden, A. E., & Schinkel, A. H. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.010439 · Cited by 228
Jonker, J. W., Wagenaar, E., Mol, C. A. A. M., Buitelaar, M., Koepsell, H., Smit, J. W., & Schinkel, A. H. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.16.5471-5477.2001 · Cited by 227
Biliary excretion in primary rat hepatocytes cultured in a collagen-sandwich configuration
Liu, X., LeCluyse, E. L., Brouwer, K. R., Gan, L.-S. L., Lemasters, J. J., Stieger, B., Meier, P. J., & Brouwer, K. L. R. (1999) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1999.277.1.g12 · Cited by 226
Self-citationThe drug efflux–metabolism alliance: biochemical aspects
Benet, L. Z., & Cummins, C. L. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00178-8 · Cited by 226
Self-citationABCG2: structure, function and role in drug response
Polgar, O., Robey, R. W., & Bates, S. E. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.1.1 · Cited by 224
In vitro-in vivo Extrapolation of Transporter-mediated Clearance in the Liver and Kidney
Kusuhara, H., & Sugiyama, Y. (2009) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.24.37 · Cited by 224
Self-citationP-Glycoprotein Recognition of Substrates and Circumvention through Rational Drug Design
Raub, T. J. (2006) · Molecular Pharmaceutics · doi:10.1021/mp0500871 · Cited by 221
van Herwaarden, A. E., & Schinkel, A. H. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.11.007 · Cited by 214
Cui, Y., König, J., & Keppler, D. (2001) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12502-3 · Cited by 206
Self-citationMultidrug resistance and the role of P-glycoprotein knockout mice
Schinkel, A. H., Mol, C. A. A. M., Wagenaar, E., van Deemter, L., Smit, J. J. M., & Borst, P. (1995) · European Journal of Cancer · doi:10.1016/0959-8049(95)00130-b · Cited by 199
Merino, G., Álvarez, A. I., Pulido, M. M., Molina, A. J., Schinkel, A. H., & Prieto, J. G. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.008219 · Cited by 199
Mechanisms of pH-gradient driven transport mediated by organic anion polypeptide transporters
Leuthold, S., Hagenbuch, B., Mohebbi, N., Wagner, C. A., Meier, P. J., & Stieger, B. (2009) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00436.2008 · Cited by 193
Pharmacokinetic Interactions of Cimetidine 1987
Somogyi, A., & Muirhead, M. (1987) · Clinical Pharmacokinetics · doi:10.2165/00003088-198712050-00002 · Cited by 191
Matsushima, S., Maeda, K., Kondo, C., Hirano, M., Sasaki, M., Suzuki, H., & Sugiyama, Y. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.085589 · Cited by 190
Self-citationAhlin, G., Karlsson, J., Pedersen, J. M., Gustavsson, L., Larsson, R., Matsson, P., Norinder, U., Bergström, C. A. S., & Artursson, P. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8003152 · Cited by 190
A regulatory viewpoint on transporter-based drug interactions
Zhang, L., Zhang, Y. (. )., Strong, J. M., Reynolds, K. S., & Huang, S.-M. (2008) · Xenobiotica · doi:10.1080/00498250802017715 · Cited by 188
Self-citationLetschert, K., Keppler, D., & König, J. (2004) · Pharmacogenetics · doi:10.1097/01.fpc.0000114744.08559.92 · Cited by 187
Self-citationDrug interactions at the blood-brain barrier: Fact or fantasy?☆
Eyal, S., Hsiao, P., & Unadkat, J. D. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.03.017 · Cited by 186
Zhou, K., Donnelly, L. A., Kimber, C. H., Donnan, P. T., Doney, A. S. F., Leese, G., Hattersley, A. T., McCarthy, M. I., Morris, A. D., Palmer, C. N. A., et al. (2009) · Diabetes · doi:10.2337/db08-0896 · Cited by 184
Global Analysis of Genetic Variation in SLCO1B1
Pasanen, M. K., Neuvonen, P. J., & Niemi, M. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.1.19 · Cited by 183
Self-citationEffect of Breast Cancer Resistance Protein (Bcrp/Abcg2) on the Disposition of Phytoestrogens
Enokizono, J., Kusuhara, H., & Sugiyama, Y. (2007) · Molecular Pharmacology · doi:10.1124/mol.107.034751 · Cited by 182
Self-citationIshiguro, N., Maeda, K., Kishimoto, W., Saito, A., Harada, A., Ebner, T., Roth, W., Igarashi, T., & Sugiyama, Y. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.009175 · Cited by 178
Self-citationMerino, G., van Herwaarden, A. E., Wagenaar, E., Jonker, J. W., & Schinkel, A. H. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.011080 · Cited by 178
Carcinogen and Anticancer Drug Transport by Mrp2 in Vivo: Studies Using Mrp2 (Abcc2) Knockout Mice
Vlaming, M. L. H., Mohrmann, K., Wagenaar, E., de Waart, D. R., Elferink, R. P. J. O., Lagas, J. S., van Tellingen, O., Vainchtein, L. D., Rosing, H., Beijnen, J. H., et al. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.101774 · Cited by 177
Effect of () variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers
CHUNG, J., CHO, J., YU, K., KIM, J., OH, D., JUNG, H., LIM, K., MOON, K., SHIN, S., & JANG, I. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.07.003 · Cited by 170
Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers*1
DING, R. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.02.008 · Cited by 169
Mechanism of multidrug recognition by MDR1/ABCB1
Kimura, Y., Morita, S., Matsuo, M., & Ueda, K. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00538.x · Cited by 168
Yamasaki, Y., Ieiri, I., Kusuhara, H., Sasaki, T., Kimura, M., Tabuchi, H., Ando, Y., Irie, S., Ware, J., Nakai, Y., et al. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100459 · Cited by 167
Self-citationClinical Pharmacokinetics of Ranolazine
Jerling, M. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645050-00003 · Cited by 165
Maeda, K., & Sugiyama, Y. (2008) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.23.223 · Cited by 165
Self-citationLu, H., Choudhuri, S., Ogura, K., Csanaky, I. L., Lei, X., Cheng, X., Song, P.-Z., & Klaassen, C. D. (2008) · Toxicological Sciences · doi:10.1093/toxsci/kfn038 · Cited by 163
Zaher, H., Khan, A. A., Palandra, J., Brayman, T. G., Yu, L., & Ware, J. A. (2006) · Molecular Pharmaceutics · doi:10.1021/mp050113v · Cited by 162
Self-citationDrug/Drug Interaction Between Lopinavir/Ritonavir and Rosuvastatin in Healthy Volunteers
Kiser, J. J., Gerber, J. G., Predhomme, J. A., Wolfe, P., Flynn, D. M., & Hoody, D. W. (2008) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e318160a542 · Cited by 160
Nozaki, Y., Kusuhara, H., Kondo, T., Iwaki, M., Shiroyanagi, Y., Nakayama, H., Horita, S., Nakazawa, H., Okano, T., & Sugiyama, Y. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.121491 · Cited by 158
Self-citationSm, H., & Temple, R. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.144 · Cited by 157
Hoffmaster, K. A., Turncliff, R. Z., LeCluyse, E. L., Kim, R. B., Meier, P. J., & Brouwer, K. L. R. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000033018.97745.0d · Cited by 156
Self-citationIsmair, M. G., Stieger, B., Cattori, V., Hagenbuch, B., Fried, M., Meier, P. J., & Kullak-Ublick, G. A. (2001) · Gastroenterology · doi:10.1053/gast.2001.28704 · Cited by 156
Scientific Perspectives on Drug Transporters and Their Role in Drug Interactions
Zhang, L., Strong, J. M., Qiu, W., Lesko, L. J., & Huang, S. M. (2006) · Molecular Pharmaceutics · doi:10.1021/mp050095h · Cited by 153
Self-citationUrquhart, B. L., Ware, J. A., Tirona, R. G., Ho, R. H., Leake, B. F., Schwarz, U. I., Zaher, H., Palandra, J., Gregor, J. C., Dresser, G. K., et al. (2008) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3282f974dc · Cited by 150
Self-citationABCB1 Pharmacogenetics: Progress, Pitfalls, and Promise
Chinn, L. W., & Kroetz, D. L. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100052 · Cited by 147
Xenobiotic Transporters: Ascribing Function from Gene Knockout and Mutation Studies
Klaassen, C. D., & Lü, H. (2007) · Toxicological Sciences · doi:10.1093/toxsci/kfm214 · Cited by 146
Characterization of Mice Lacking the Multidrug Resistance Protein Mrp2 (Abcc2)
Chu, X., Strauss, J. R., Mariano, M. A., Li, J., Newton, D. J., Cai, X., Wang, R. W., Yabut, J. A., Hartley, D. P., Evans, D. C., et al. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.098665 · Cited by 145
Self-citationMatsson, P., Englund, G., Ahlin, G., Bergström, C. A. S., Norinder, U., & Artursson, P. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.124768 · Cited by 143
Oostendorp, R. L., Buckle, T., Beijnen, J. H., van Tellingen, O., & Schellens, J. H. M. (2008) · Investigational New Drugs · doi:10.1007/s10637-008-9138-z · Cited by 137
Vallon, V., Rieg, T., Ahn, S.-Y., Wu, W., Eraly, S. A., & Nigám, S. K. (2008) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00528.2007 · Cited by 133
Physiology, structure, and regulation of the cloned organic anion transporters
Srimaroeng, C., Perry, J. L., & Pritchard, J. B. (2008) · Xenobiotica · doi:10.1080/00498250801927435 · Cited by 132
Kanamitsu, S.-I., Ito, K., & Sugiyama, Y. (2000) · Pharmaceutical Research · doi:10.1023/a:1007509324428 · Cited by 130
Self-citationBCRP Transports Dipyridamole and is Inhibited by Calcium Channel Blockers
Zhang, Y., Gupta, A., Wang, H., Zhou, L., Vethanayagam, R. R., Unadkat, J. D., & Mao, Q. (2005) · Pharmaceutical Research · doi:10.1007/s11095-005-8384-4 · Cited by 130
Sanna, S., Busonero, F., Maschio, A., McArdle, P. F., Usala, G., Dei, M., Lai, S., Mulas, A., Piras, M. G., Perseu, L., et al. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp203 · Cited by 128
Ciarimboli, G. (2008) · Xenobiotica · doi:10.1080/00498250701882482 · Cited by 128
Role of organic cation transporters in the renal handling of therapeutic agents and xenobiotics
Wright, S. H. (2005) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.10.021 · Cited by 127
Self-citationWire, M. B., Shelton, M. J., & Studenberg, S. D. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645020-00002 · Cited by 127
Zheng, H., Huang, Y. L., Frassetto, L. A., & Benet, L. Z. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.186 · Cited by 125
Self-citationvan de Steeg, E., van der Kruijssen, C. M. M., Wagenaar, E., Burggraaff, J. E. C., Mesman, E. M., Kenworthy, K. E., & Schinkel, A. H. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.024315 · Cited by 125
Li, M., Yuan, H., Li, N., Song, G., Zheng, Y. Z., Baratta, M., Hua, F., Thurston, A., Wang, J., & Lai, Y. (2008) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2008.06.008 · Cited by 121
Zaher, H., zu Schwabedissen, H. E. M., Tirona, R. G., Cox, M. L., Obert, L., Agrawal, N., Palandra, J., Stock, J. L., Kim, R. B., & Ware, J. A. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.046458 · Cited by 117
Self-citationEffects of probenecid on the pharmacokinetics and elimination of acyclovir in humans
Laskin, O. L., de Miranda, P., King, D. H., Page, D. A., Longstreth, J. A., Rocco, L., & Lietman, P. S. (1982) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.21.5.804 · Cited by 116
Pharmacophore-based discovery of ligands for drug transporters
Chang, C. K., Ekins, S., Bahadduri, P. M., & Swaan, P. W. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.09.006 · Cited by 116
Self-citationIn Vitro–In Vivo Correlation of Hepatobiliary Drug Clearance in Humans
Ghibellini, G., Vasist, L., Leslie, E. M., Heizer, W. D., Kowalsky, R. J., Calvo, B. F., & Brouwer, K. L. R. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100059 · Cited by 115
Self-citationZamek‐Gliszczynski, M. J., Nezasa, K.-I., Tian, X., Kalvass, J. C., Patel, N. J., Raub, T. J., & Brouwer, K. L. R. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.026955 · Cited by 113
Self-citationPaine, S. W., Parker, A. J., Gardiner, P., Webborn, P. J. H., & Riley, R. J. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.019455 · Cited by 112
Predicting P-glycoprotein substrates by a quantitative structure–activity relationship model
Gombar, V. K., Polli, J. W., Humphreys, J. E., Wring, S. A., & Serabjit‐Singh, C. J. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20035 · Cited by 112
Self-citationEffects of Atazanavir/Ritonavir or Fosamprenavir/Ritonavir on the Pharmacokinetics of Rosuvastatin
Busti, A. J., Bain, A. M., Hall, R. G., Bedimo, R. G., Leff, R. D., Meek, C. C., & Mehvar, R. (2008) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e31817b5b5a · Cited by 107
[45] Transport function and substrate specificity of multidrug resistance protein
KEPPLER, D. O. R., Jedlitschky, G., & Leier, I. (1998) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(98)92047-x · Cited by 106
Self-citationMarion, T. L., Leslie, E. M., & Brouwer, K. L. R. (2007) · Molecular Pharmaceutics · doi:10.1021/mp0700357 · Cited by 100
Self-citationKatz, D. A., Carr, R. A., GRIMM, D., Xiong, H., Holley-Shanks, R. R., MUELLER, T., Leake, B. F., WANG, Q., Han, L., & WANG, P. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.11.003 · Cited by 99
Drugdrug interactions involving membrane transporters in the human kidney
Li, M., Anderson, G. D., & Wang, J. (2006) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2.4.505 · Cited by 99
Ghibellini, G., Leslie, E. M., Pollack, G. M., & Brouwer, K. L. R. (2008) · Pharmaceutical Research · doi:10.1007/s11095-008-9597-0 · Cited by 99
Self-citationSasaki, M., Suzuki, H., Aoki, J., Ito, K., Meier, P. J., & Sugiyama, Y. (2004) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)05627-x · Cited by 96
Self-citationTruong, D. M., Kaler, G. V., Khandelwal, A., Swaan, P. W., & Nigám, S. K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m708615200 · Cited by 96
Self-citationAoki, M., Terada, T., Kajiwara, M., Ogasawara, K., Ikai, I., Ogawa, O., Katsura, T., & Inui, K. (2008) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.90257.2008 · Cited by 94
Hedman, M. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.09.011 · Cited by 93
Xiang, X., Jada, S. R., Li, H. H., Fan, L., Tham, L. S., Wong, C. I., Lee, S. C., Lim, R. S. C., Zhou, Q. Y., Goh, B. C., et al. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000230420.05221.71 · Cited by 93
Feng, B., Obach, R., Burstein, A., Clark, D., de Morais, S., & Faessel, H. M. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100405 · Cited by 93
Takano, A., Kusuhara, H., Suhara, T., Ieiri, I., Morimoto, T., Lee, Y. J., Maeda, J., Ikoma, Y., Ito, H., Suzuki, K., et al. (2006) · PubMed · Cited by 93
Self-citationSaito, H., Hirano, H., Nakagawa, H., Fukami, T., Oosumi, K., Murakami, K., Kimura, H., Kouchi, T., Konomi, M., Tao, E., et al. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.099036 · Cited by 92
Self-citationStructural Variation Governs Substrate Specificity for Organic Anion Transporter (OAT) Homologs
Kaler, G. V., Truong, D. M., Khandelwal, A., Nagle, M. A., Eraly, S. A., Swaan, P. W., & Nigám, S. K. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703467200 · Cited by 91
Self-citationMatsushima, S., Maeda, K., Ishiguro, N., Igarashi, T., & Sugiyama, Y. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.017814 · Cited by 88
Self-citationQSAR analysis and molecular modeling of ABCG2-specific inhibitors
Nicolle, E., Boumendjel, A., Macalou, S., Genoux‐Bastide, E., Ahmed‐Belkacem, A., Carrupt, P., & Pietro, A. D. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.10.004 · Cited by 83
Drug and toxicant handling by the OAT organic anion transporters in the kidney and other tissues
Nigám, S. K., Bush, K. T., & Bhatnagar, V. (2007) · Nature Reviews Nephrology · doi:10.1038/ncpneph0558 · Cited by 83
Zamek‐Gliszczynski, M. J., Hoffmaster, K. A., Humphreys, J. E., Tian, X., Nezasa, K.-I., & Brouwer, K. L. R. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.101840 · Cited by 81
Self-citationPharmacogenomic Importance of ABCG2
Cusatis, G., & Sparreboom, A. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.8.1005 · Cited by 79
Abe, K., Bridges, A. S., & Brouwer, K. L. R. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.023465 · Cited by 77
Self-citationSasaki, K., Makita, N., Sunami, A., Sakurada, H., Shirai, N., Yokoi, H., Kimura, A., Tohse, N., Hiraoka, M., & Kitabatake, A. (2004) · Molecular Pharmacology · doi:10.1124/mol.66.2.330 · Cited by 74
Gui, C., & Hagenbuch, B. (2008) · Biochemistry · doi:10.1021/bi8008455 · Cited by 72
Uchida, Y., Kamiie, J., Ohtsuki, S., & Terasaki, T. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9453-7 · Cited by 72
Watanabe, T., Maeda, K., Kondo, T., Nakayama, H., Horita, S., Kusuhara, H., & Sugiyama, Y. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.026062 · Cited by 72
Self-citationMaeda, A., Tsuruoka, S., Kanai, Y., Endou, H., Saito, K., Miyamoto, E., & Fujimura, A. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.08.023 · Cited by 71
Letschert, K., Komatsu, M., Hummel-Eisenbeiss, J., & KEPPLER, D. O. R. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.081224 · Cited by 71
Self-citationIns and outs of the ABCG2 multidrug transporter: An update on in vitro functional assays
Hegedüs, C., Szakács, G., Homolya, L., Orbán, T. I., Telbisz, Á., Jani, M., & Sarkadi, B. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.09.007 · Cited by 71
PhRMA White Paper on ADME Pharmacogenomics
Williams, J. A., Andersson, T., Andersson, T. B., Blanchard, R. L., Behm, M. O., Cohen, N., Edeki, T. I., Franc, M. A., Hillgren, K. M., Johnson, K. J., et al. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270008319329 · Cited by 69
Self-citationOswald, S., Scheuch, E., Cascorbi, I., & Siegmund, W. (2005) · Journal of Chromatography B · doi:10.1016/j.jchromb.2005.10.034 · Cited by 69
Relationship between Drug/Metabolite Exposure and Impairment of Excretory Transport Function
Zamek‐Gliszczynski, M. J., Kalvass, J. C., Pollack, G. M., & Brouwer, K. L. R. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.023648 · Cited by 69
Self-citationAbel, S., Nichols, D. J., Brearley, C. J., & Eve, M. D. (2000) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2000.00114.x · Cited by 68
Human ABC Transporter ABCG2 in Xenobiotic Protection and Redox Biology
Wakabayashi, K., Tamura, A., Saito, H., Onishi, Y., & Ishikawa, T. (2006) · Drug Metabolism Reviews · doi:10.1080/03602530600727947 · Cited by 66
Self-citationPoirier, A., Funk, C., Scherrmann, J., & Lavé, T. (2009) · Molecular Pharmaceutics · doi:10.1021/mp8002495 · Cited by 66
Predictors of Vinorelbine Pharmacokinetics and Pharmacodynamics in Patients With Cancer
Wong, M. K., Balleine, R. L., Blair, E. Y. L., McLachlan, A. J., Ackland, S. P., Garg, M. B., Evans, S., FARLOW, D. C., Collins, M., Rivory, L. P., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.1295 · Cited by 64
In Vitro and Pharmacophore-Based Discovery of Novel hPEPT1 Inhibitors
Ekins, S., Johnston, J. S., Bahadduri, P. M., D’Souza, V. M., Ray, A., Chang, C. K., & Swaan, P. W. (2005) · Pharmaceutical Research · doi:10.1007/s11095-005-2505-y · Cited by 63
Self-citationBlood–brain barrier transport of pramipexole, a dopamine D2 agonist
Okura, T., Ito, R., Ishiguro, N., Tamai, I., & Deguchi, Y. (2007) · Life Sciences · doi:10.1016/j.lfs.2007.01.035 · Cited by 63
Loo, T. W., Bartlett, M. C., & Clarke, D. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400229200 · Cited by 62
Sai, Y. (2005) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.20.91 · Cited by 60
Stereoselective inhibition of pindolol renal clearance by cimetidine in humans
Somogyi, A. A., Bochner, F., & Sallustio, B. C. (1992) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1992.37 · Cited by 56
Pharmacogenetics of Membrane Transporters: A Review of Current Approaches
Sissung, T. M., Goey, A. K. L., Ley, A. M., Strope, J. D., & Figg, W. D. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-0956-8_6 · Cited by 56
Hendrikse, N. H., Kuipers, F., Meijer, C., Havinga, R., Bijleveld, C. M. A., van der Graaf, W. T. A., Vaalburg, W., & de Vries, E. G. E. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0793-2 · Cited by 54
Future directions for drug transporter modelling
Ekins, S., Ecker, G. F., Chiba, P., & Swaan, P. W. (2007) · Xenobiotica · doi:10.1080/00498250701646341 · Cited by 54
Self-citationTsuruoka, S., Ioka, T., WAKAUMI, M., Sakamoto, K., OOKAMI, H., & Fujimura, A. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.12.302 · Cited by 53
Effect of cimetidine and probenecid on pilsicainide renal clearance in humans
Shiga, T., Hashiguchi, M., Urae, A., Kasanuki, H., & Rikihisa, T. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.104018 · Cited by 52
Uptake and Efflux Transporters for Conjugates in Human Hepatocytes
KEPPLER, D. O. R. (2005) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(05)00029-7 · Cited by 50
Self-citationIshikawa, T., Sakurai, A., Kanamori, Y., Nagakura, M., Hirano, H., Takarada, Y., Yamada, K., Fukushima, K., & Kitajima, M. (2005) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(05)00027-3 · Cited by 48
Self-citationSauvant, C., Hesse, D., Holzinger, H., Evans, K. K., Dantzler, W. H., & Gekle, M. (2004) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00326.2003 · Cited by 46
Cited by
Why 90% of clinical drug development fails and how to improve it?
Sun, D., Gao, W., Hu, H., & Zhou, S. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.02.002 · Cited by 1,763
Kim, H. J., Huh, D., Hamilton, G., & Ingber, D. E. (2012) · Lab on a Chip · doi:10.1039/c2lc40074j · Cited by 1,734
An atlas of genetic influences on human blood metabolites
The Multiple Tissue Human Expression Resource (MuTHER) Consortium, Shin, S.-Y., Fauman, E. B., Petersen, A.-K., Krumsiek, J., Santos, R., Huang, J., Arnold, M., Erte, I., Forgetta, V., et al. (2014) · Nature Genetics · doi:10.1038/ng.2982 · Cited by 1,515
Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280
Self-citationLöscher, W., Potschka, H., Sisodiya, S. M., & Vezzani, A. (2020) · Pharmacological Reviews · doi:10.1124/pr.120.019539 · Cited by 903
Metadata
- Authors
- The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., Hillgren, K. M., Hoffmaster, K. A., Ishikawa, T., Keppler, D., Kim, R. B., Lee, C. A., Niemi, M., Polli, J. W., Sugiyama, Y., Swaan, P. W., Ware, J. A., Wright, S. H., Wah Yee, S., Zamek-Gliszczynski, M. J., & Zhang, L.
- Affiliations
- University of California, San Francisco (US)
- United States Food and Drug Administration (US)
- Boehringer Ingelheim (United States) (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Abbott (United States) (US)
- Eli Lilly (United States) (US)
- Novartis (United States) (US)
- RIKEN (JP)
- German Cancer Research Center (DE)
- Western University (CA)
- GlaxoSmithKline (United Kingdom) (GB)
- Genentech (US)
- University of Maryland, Baltimore (US)
- University of Arizona (US)
- ORCID
- Venue
- Nature Reviews Drug Discovery
- Published
- 2010-03
- Volume
- 9
- Issue
- 3
- Pages
- 215-236
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- PMC
- PMC3326076
- OpenAlex
- W2079197876
- Cited by
- 3,340
- References
- 225
- Citations by year
- 2026: 105 · 2025: 118 · 2024: 153 · 2023: 175 · 2022: 180 · 2021: 237 · 2020: 187 · 2019: 219 · 2018: 234 · 2017: 216 · 2016: 242 · 2015: 233 · 2014: 248 · 2013: 316 · 2012: 254
- FWCI
- 27.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Scholarship@Western (Western University) (submittedVersion)
- Funders
- National Institutes of Health (GM61390)
- U.S. Food and Drug Administration
- National Institute of General Medical Sciences (GM61390, R01GM041935, U19GM061390, U01GM061390)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK080801, R01DK061425)
- National Institute of Environmental Health Sciences (P30ES006694)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Keywords
- membrane transporters, drug transporters, drug-drug interactions, pharmacokinetics, drug absorption, drug disposition, drug development, drug safety and efficacy, drug labeling
- MeSH terms
- Animals, Computer Simulation, Decision Trees, Drug Interactions, Drug Evaluation, Preclinical, Humans, Drug Approval, Mice, Knockout, Membrane Transport Proteins, Mice, Prescription Drugs, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.